[{"id":"18969080-8eb0-4d96-a700-a81dd448f550","acronym":"SINTART2","url":"https://clinicaltrials.gov/study/NCT02099188","created_at":"2021-07-13T21:53:06.604Z","updated_at":"2024-07-02T16:35:53.438Z","phase":"Phase 2","brief_title":"Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Inoperable Patients","source_id_and_acronym":"NCT02099188 - SINTART2","lead_sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","biomarkers":" TP53","pipe":"","alterations":" ","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • docetaxel • 5-fluorouracil • doxorubicin hydrochloride • ifosfamide • etoposide IV • leucovorin calcium"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 11/01/2013","start_date":" 11/01/2013","primary_txt":" Primary completion: 06/01/2020","primary_completion_date":" 06/01/2020","study_txt":" Completion: 01/01/2024","study_completion_date":" 01/01/2024","last_update_posted":"2023-03-13"},{"id":"c76b2924-526d-4c0c-91ca-abc674c755d0","acronym":"SINTART 1","url":"https://clinicaltrials.gov/study/NCT02099175","created_at":"2021-07-13T21:53:06.298Z","updated_at":"2024-07-02T16:35:53.426Z","phase":"Phase 2","brief_title":"Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Operable Patients","source_id_and_acronym":"NCT02099175 - SINTART 1","lead_sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","biomarkers":" TP53","pipe":"","alterations":" ","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • docetaxel • 5-fluorouracil • doxorubicin hydrochloride • ifosfamide • etoposide IV • leucovorin calcium"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 41","initiation":"Initiation: 11/01/2013","start_date":" 11/01/2013","primary_txt":" Primary completion: 01/01/2020","primary_completion_date":" 01/01/2020","study_txt":" Completion: 01/01/2024","study_completion_date":" 01/01/2024","last_update_posted":"2023-03-13"},{"id":"97993249-9b0e-4d8d-becd-cd4dbf8ec23d","acronym":"TAXYNERGY","url":"https://clinicaltrials.gov/study/NCT01718353","created_at":"2021-01-18T07:29:43.577Z","updated_at":"2024-07-02T16:37:16.210Z","phase":"Phase 2","brief_title":"Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)","source_id_and_acronym":"NCT01718353 - TAXYNERGY","lead_sponsor":"Sanofi","biomarkers":" AR","pipe":"","alterations":" ","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • prednisone • cabazitaxel"],"overall_status":"Completed","enrollment":" Enrollment 63","initiation":"Initiation: 03/01/2013","start_date":" 03/01/2013","primary_txt":" Primary completion: 08/01/2015","primary_completion_date":" 08/01/2015","study_txt":" Completion: 08/01/2015","study_completion_date":" 08/01/2015","last_update_posted":"2017-11-20"}]